Development of MEDI4736, an anti-programmed cell death ligand 1 PD-L1 antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer NSCLCReportar como inadecuado




Development of MEDI4736, an anti-programmed cell death ligand 1 PD-L1 antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer NSCLC - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal for ImmunoTherapy of Cancer

, 2:P179

First Online: 06 November 2014DOI: 10.1186-2051-1426-2-S3-P179

Cite this article as: Brahmer, J., Balmanoukian, A., Goldberg, S. et al. j. immunotherapy cancer 2014 2Suppl 3: P179. doi:10.1186-2051-1426-2-S3-P179 Download fulltext PDF



Autor: Julie Brahmer - Ani Balmanoukian - Sarah Goldberg - Sai-Hong Ou - Andrew Blake-Haskins - Joyson Karakunnel - Paul Stockman

Fuente: https://link.springer.com/







Documentos relacionados